Mobile

Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017688-40

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

In each group: 1) To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the ID influenza vaccine NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 2) To describe the safety of the corresponding strength of the ID influenza vaccine, NH 2010-2011 formulation

Critère d'inclusion

  • Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intraderma route

Liens